Filing Flows › Altimmune (ALT) › Q4 2025
Altimmune (ALT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 6, 2026
Altimmune (ALT) reported revenue of $26K for the fourth quarter 2025 (Q4 2025), +420% from a year earlier and +420% from the quarter before.
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26K | +420% | +420% |
| Operating profit | −$28.9M | — | — |
| Net earnings | −$27.4M | — | — |
| Operating cash flow | −$19.4M | — | — |
What changed
Revenue was $26K in Q4 2025, up 420% year over year and up 420% from the previous quarter.
Operating costs exceeded revenue by $28.9M, an operating margin of -111126.9%. Total costs grew 16% against revenue growth of 420%. The fastest-growing cost line was General & admin (+106%). The quarter ended with a net loss of $27.4M, wider than the previous quarter's $19.0M loss.
Operating cash flow was −$19.4M. Non-cash charges added back $26K of depreciation and $4.9M of share-based compensation. Working capital and other items added $2.9M. Capital expenditures of $1K exceeded it, leaving free cash flow of −$19.4M.
Questions
What was Altimmune's revenue in the fourth quarter 2025?
Altimmune (ALT) reported revenue of $26K for the fourth quarter 2025 (Q4 2025), +420% from a year earlier and +420% from the quarter before.
Source: Altimmune 10-K on SEC EDGAR.